Overtreatment in XXXX : adverse consequences and mechanisms.

@entity1 @entity410 @entity137 @entity1092 @entity2049 @entity302 @entity2812 @entity2359
The most important determinant of quality of life in @entity1 with @entity302 is complete @entity410 control, and therefore this should be the ultimate goal of pharmacological therapy. @entity410 freedom, or a reduction in @entity410 frequency, however, should not be sought at all costs, and the situation should never arise where a @entity1 with @entity302 is made to suffer more from the side effects of treatment than from the consequences of the underlying disease. Overtreatment is not uncommon in patients taking antiepileptic drugs, and it may occur in many forms and with a variety of mechanisms. Long-term use (or continuation) of anticonvulsant therapy in situations where it is not indicated (e.g. in @entity1 with @entity410 , or in non-epileptic @entity410 -free @entity1 who underwent brain surgery) constitutes a blatant case of overtreatment. Other forms of overtreatment include the use of unnecessarily fast dose escalation rates, which may expose the @entity1 to potentially serious or severe side effects, or the prescription of unnecessarily high maintenance dosages. The latter occurrence may result from inadequate understanding of dose-response relationships, from misinterpretation of serum drug concentrations (e.g. targeting concentrations within the 'range' in @entity1 who are well controlled at lower concentrations) or, at times, from failure to recognize a paradoxical increase in @entity410 frequency as a manifestation of @entity137 . The most common form of overtreatment, however, involves the unnecessary use of combination therapy (polypharmacy) in @entity1 who could be treated optimally with a single drug. Adverse effects associated with polypharmacy often result from undesirable drug-drug interactions. While pharmacokinetic interactions are somewhat predictable and can be minimized or controlled by monitoring serum drug concentrations and/or dose adjustment, pharmacodynamic interactions leading to enhanced @entity2359 (as seen, for example, in some @entity1 given a combination of @entity2812 and @entity2049 ) can only be identified by careful clinical observation. There is evidence that not all antiepileptic drug combinations are equally adverse, and that the combined use of specific drugs (e.g. @entity2812 and @entity1092 ) may even exhibit an improved therapeutic index compared with either agent given alone, provided appropriate dose adjustments are made. Although the suggestion has been made that adverse effects are more likely to result from combining anticonvulsants having a similar mode of action, our knowledge of the pharmacology of individual agents is insufficient to allow a reliable prediction of the clinical effects of specific drug combinations.
